Reliv’ International (OTCMKTS:RELV) vs. Zymeworks (NASDAQ:ZYME) Head to Head Comparison

Zymeworks (NASDAQ:ZYME) and Reliv’ International (OTCMKTS:RELV) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Volatility & Risk

Zymeworks has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Zymeworks and Reliv’ International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1	1	9	2	2.92
Reliv’ International	0	0	0	0	0.00

Zymeworks presently has a consensus price target of $38.00, suggesting a potential upside of 59.07%. Given Zymeworks’ stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Reliv’ International.

Profitability

This table compares Zymeworks and Reliv’ International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Reliv’ International	-0.61%	-1.89%	-1.31%

Valuation & Earnings

This table compares Zymeworks and Reliv’ International”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96 million	16.46	-$81.13 million	($1.37)	-17.44
Reliv’ International	$35.06 million	0.10	-$440,000.00	($0.09)	-22.22

Reliv’ International has lower revenue, but higher earnings than Zymeworks. Reliv’ International is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 7.8% of Reliv’ International shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 30.0% of Reliv’ International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zymeworks beats Reliv’ International on 10 of the 15 factors compared between the two stocks.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.